Allevion Medical has gained U.S. Food and Drug Administration (FDA) clearance of Vantage, a fully disposable, sterile system designed to simplify and enhance minimally invasive lumbar decompression procedures.

Vantage was developed to address pain related to hypertrophic bone growth. It allows targeted decompression through a patented approach that combines precision with procedural control, the company said.

The system follows a “locate, dilate, decompress” workflow that helps physicians perform with more consistency and efficiency. The structured approach supports safety while letting surgeons efficiently remove hypertrophic bone from the lamina and facet joints that can contribute to spinal canal narrowing.

Traditional decompression procedures often require larger incisions and bulky instrumentation to retract tissue, which may increase the risk of scar tissue formation, prolonged recovery, and chronic pain. These approaches typically rely on multiple instrument trays that must be cleaned, sterilized prior to surgery.

Other minimally invasive systems focus primarily on soft tissue removal, such as the ligamentum flavum alone, which may not provide sufficient decompression when hypertrophic bone is a primary contributor to stenosis.

Vantage’s key differentiator is its direct visualization capability, which is bolstered by single-use integrated illumination to visualize targeted anatomy throughout the surgery.

“Vantage provides physicians with a streamlined and reliable solution for treating lumbar spinal stenosis,” Allevion Medical said in a press release. “Its single-use design, structured workflow, and integrated visualization capabilities help establish a new standard for efficiency, control, and consistency in spinal decompression procedures.